Find information on thousands of medical conditions and prescription drugs.

Ergoloid Mesylates

Ergoloid mesylates (Brand names: Hydergine, Gerimal, Niloric, Redizork) (Chemical name: Dihydroergotoxine mesylate) are dihydrogenated ergot alkaloids used to combat decreased mental function as a result of senility or multiple small strokes.

While the exact method of its action is not known, dihydroergotoxine stimulates dopaminergic and serotoninergic receptors and blocks alpha-adrenoreceptors.

Home
Diseases
Medicines
A
B
C
D
E
E-Base
Ecstasy (drug)
Edecrin
Edrophonium
Edrophonium chloride
Efavirenz
Effexor
Eflornithine
Elavil
Eldepryl
Elidel
Eligard
Elitek
Elixomin
Elixophyllin
Ellagic acid
Elmiron
Eloxatin
Elspar
Emtriva
Emylcamate
Enalapril
Enalaprilat
Enalaprilat
Endep
Enflurane
Enoxaparin sodium
Entacapone
Enulose
Epi-pen
Epinephrine
Epirubicin
Epitol
Epivir
Epogen
Eprosartan
Ergocalciferol
Ergoloid Mesylates
Ergotamine
Eryc
Eryped
Erythromycin
Esgic
Eskalith
Esmolol
Estazolam
Estazolam
Estrace
Estraderm
Estradiol
Estradiol
Estradiol valerate
Estring
Estrogel
Estrone
Estrostep
Ethacridine
Ethambutol
Ethchlorvynol
Ethosuximide
Ethotoin
Etiracetam
Etodolac
Etopophos
Etoposide
Etorphine
Evista
Exelon
Exemestane
Hexal Australia
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Read more at Wikipedia.org


[List your site here Free!]


Alzheimer's drug ineffective - ergoloid mesylates, petition to ban drug
From Healthfacts, 3/1/91

The disturbing discovery that the only drug approved by the FDA to treat people with Alzheimer's disease, ergoloid mesylates (brand names: Hydergine, Hydergine LC, Deapril-ST), is ineffective and may make some people worse has resulted in a petition to ban the drug. About 1.4 million Americans are severely affected by Alzheimer's disease, which has no known cause, and several million more people have milder symptoms of the disease. Ergoloid mesylates have been used for decades to treat Alzheimer's disease, which is also known as senile dementia.

The petition, filed last month with the FDA Commissioner by Ralph Nader's Public Citizen, cited a randomized, placebo-controlled study published in The New England Journal of Medicine (16 August 1990) as the first methodologically-sound study" of ergoloid mesylates. The study suggests that the drug is "ineffective, costly, and possibly harmful." The petition demands immediate "Dear Doctor" letters be sent to physicians notifying them of the drug's questionable safety and effectiveness.

The above-cited study of 80 older adults diagnosed with "probable Alzheimer's disease" randomized half of the group to Hydergine LC three times daily for six months while the other half took a placebo (sugar pill) for the same period. At the end of the study the researchers concluded that the drug produced "no notable beneficial effects on our patients." The behavioral and mental deterioration observed in both drug and placebo groups was measured by five standard tests given at the start of the study and again at 12 and 24 weeks. The research team was surprised that those taking the drug did worse on two tests than those on the placebo, although only the differences in one test were statistically significant. The investigators could only speculate that ergoloid mesylates might accelerate the progression of disease or have a previously unrecognized direct toxic effect.

COPYRIGHT 1991 Center for Medical Consumers, Inc.
COPYRIGHT 2004 Gale Group

Return to Ergoloid Mesylates
Home Contact Resources Exchange Links ebay